J.C-H. Yang , Y.J. Kim , S-H. Lee , B. Liu , Y.V. Ostapenko , S. Lu , A. Alip , E.P. Korbenfeld , J. Dias , P. Danchaivijitr , N. Girard , E. Felip , H. Hayashi , A. Spira , B. Besse , T. Sun , M. Ennis , S. Sethi , J.M. Bauml , B.C. Cho
{"title":"40: Amivantamab + lazertinib vs osimertinib治疗一线(1L) egfr突变体(EGFRm)晚期NSCLC:来自III期MARIPOSA研究的最终总生存期(OS)","authors":"J.C-H. Yang , Y.J. Kim , S-H. Lee , B. Liu , Y.V. Ostapenko , S. Lu , A. Alip , E.P. Korbenfeld , J. Dias , P. Danchaivijitr , N. Girard , E. Felip , H. Hayashi , A. Spira , B. Besse , T. Sun , M. Ennis , S. Sethi , J.M. Bauml , B.C. Cho","doi":"10.1016/S1556-0864(25)00199-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S6-S8"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study\",\"authors\":\"J.C-H. Yang , Y.J. Kim , S-H. Lee , B. Liu , Y.V. Ostapenko , S. Lu , A. Alip , E.P. Korbenfeld , J. Dias , P. Danchaivijitr , N. Girard , E. Felip , H. Hayashi , A. Spira , B. Besse , T. Sun , M. Ennis , S. Sethi , J.M. Bauml , B.C. Cho\",\"doi\":\"10.1016/S1556-0864(25)00199-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S6-S8\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425001996\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425001996","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.